About our
quality policy

About us

Our quality policy

Our business policy is focused on continuity of Biolegio BV and NimaGen BV. We are convinced that this continuity can be ensured only when the care for the environment, good working conditions and quality are an integral part of the total enterprise. Our Integrated Management System (IMS) is not only set up, but is also regularly maintained and checked on the effectiveness of our IMS. Our IMS is based on the following principles:




In terms of quality through Biolegio we deliver unique oligonucleotides, designed and as requested by our customers. Through Nimagen we deliver high quality reagents for Sanger and NGS sequencing. The product complies with the expectations of our customers. Even better is when we have surpassed all these expectations. To achieve this goal, we control our production process using our Integrated Management System. In addition, we take measures in order to maintain its effectiveness. 




Everyone should strive for continuous improvement of the results in terms of quality, working conditions and environment. These issues are of a great importance for a healthy future of both companies. The ideas of our staff and of our customers on this subject, will be very much appreciated. The Board will annually determine concrete and verifiable objectives relevant to the expectations of our customers and employees. The results are evaluated annually and new targets have been set. We will strive for continuous improvement.


Biolegio and Nimagen want to be the best in everything they do. We have set up an integrated management system that meets the highest requirements. This system will be used to manage the quality aspects of our company. We will comply with all relevant legal, business and contractual security obligations.


We will ensure that the risks, threats and vulnerabilities associated with our business are effectively identified, assessed and managed.


Our overall objective is to provide a high quality and secure service to all of our customers. We will do this by: 


  • Placing the highest value on being customer driven and meeting specific customer requirements and improving customer satisfaction;
  • Setting and monitoring achievement of specific improvement objectives;
  • Regularly reviewing service standards and focusing on improving overall efficiency and service standards;
  • Managing the quality and service management risks associated with our business;
  • Continually improving the effectiveness of our Integrated Management System                                                


Ruud van der Steen
CEO Nimagen BV




Latest news

News | 30.03.21

Press Release: NimaGen- Expanding Throughput for SARS-CoV-2 Whole Genome Sequencing

Nijmegen, The Netherlands, March 29, 2021   Following the release and success of their EasySeq™ SARS-CoV-2 WGS kit in 2020, NimaGen BV announce the further expansion of their kit range to facilitate higher throughput application of SARS-CoV-2 Whole Genome Sequencing (WGS) with the launch of a 384-sample version kit for Illumina sequencing and the addition of an expanded selection of accompanying Unique Dual Indexes (UDIs) now increased to 1536 UDIs. Rapid and Simplified Library Preparation for viral surveillanceThe recent emergence and spread of new nCoV-2 variants have clearly demonstrated the importance and need for rapid and high throughput screening for SARS-CoV-2 for viral surveillance. Utilising Reverse Complement PCR (RC-PCR), WGS library preparation with the EasySeq™ SARS-CoV-2 kit could not be simpler- with just a single PCR reaction for both Amplicon generation and indexing.Assay set-up is extremely easy and ideally suited for automation, with just 2 dispensing steps of sample and Mastermix to pre-spotted index plates before loading in the Thermocycler. Following the single PCR all samples can immediately be pooled for a single-tube magnetic bead clean-up step and once standard quality control checks have been performed the library is ready for sequencing.This drastically simplified protocol can reduce hands on time for library prep by up to 80% compared with other methods currently being used for the WGS of SARS-CoV-2. Dr Josh Quick from the Institute of Microbiology & Infection, University of Birmingham, UK and who was integrally involved in the creation of the ARTIC Network SARS-CoV-2 sequencing protocol has commented:"Multiplex RC-PCR is one of the solutions emerging from the pandemic that has excited me the most. The approach combines the robustness of amplicon sequencing with the scalability of PCR barcoding in a single PCR step, something I have puzzled over for years. In our testing the sensitivity was comparable to other amplicon based methods but with a greatly streamlined Illumina library preparation workflow and I am optimistic that there is even more performance to come with this approach in future." Simpler and more rapid library prep does allow for more samples to be prepared each day, improving public health authority’s ability to monitor the epidemic and the emergence, and spread of new variants. Sequence every positive COVID-19 Sample?“The addition of a 384 well version of the kit to the range will certainly help our high-throughput customers streamline their library preparation even further” says Joop Theelen, CSO and co-founder of NimaGen “Also, with up to 1536 accompanying UDIs now available, more than 3000 SARS-CoV-2 whole genomes could be sequenced on one Illumina NovaSeq SP dual lane flowcell – bringing the possibility to sequence every positive COVID-19 sample closer than ever before.” Future DevelopmentsNimaGen are also rapidly developing a “one-step” version of the kit that works direct on RNA samples, thus avoiding the need for a separate cDNA synthesis reaction before WGS library preparation.By adapting the RC-PCR method cDNA synthesis, amplification and indexing can be carried out in a single closed tube PCR reaction, further streamlining the complete workflow, and allowing for increased throughput.“The need for a separate cDNA synthesis step is currently a potential major workflow bottleneck for our customers and as with any additional handling step it also adds to the risks around assay and sample security” Walter van der Vliet, NGS Application & Development Scientist at NimaGen says “If we can incorporate the generation of cDNA into the RC-PCR reaction then our customers can go direct from extracted RNA to indexed amplicons in just one PCR step, making the whole workflow faster and more secure and ultimately allowing them to process more samples each day” Early development data looks positive and NimaGen expects to have the product commercially available in spring 2021.Further details available at www.nimagen.com/covid19